Treeline Biosciences
- Sector
- Biotech
- Headquarters
- WATERTOWN, MA
- Founded
- 2021
- Latest Form D
- $200M, Sep 2025
- Total capital
- $1.1B
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $1.1B
- 4 Form D · last Sep 2025
- 14 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 40 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 4th filing$200M
- Private capital raisedForm D · SEC · 3rd filing$422M
- Private capital raisedForm D · SEC · 2nd filing$261M
- Private capital raisedForm D · SEC · 1st filing$212M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
From SEC Form D filings- Aftab H. KheraniDirectorNamed in SEC Form D filings
- Ali H. SatvatDirectorNamed in SEC Form D filings
- Avi H. NaiderDirectorNamed in SEC Form D filings
- David H. BonitaDirectorNamed in SEC Form D filings
- David H. SchenkeinDirectorNamed in SEC Form D filings
- Jeffrey H. EngelmanExecutive Officer, Director, PromoterNamed in SEC Form D filings
Show all 9 people
- Joshua H. BilenkerExecutive Officer, Director, PromoterNamed in SEC Form D filings
- Kristina H. BurowDirectorNamed in SEC Form D filings
- Steven H. ElmsDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 40- PendingTricyclic Quinolone BCL6 Bifunctional DegradersUSPTOApplication 19659274
- Pending1,8-NAPHTHYRIDIN-2-ONE Heterobifunctional BCL6 DegradersUSPTOApplication 18874504
- PendingSpirocyclic Dihydropyranopyrimidine Kras InhibitorsUSPTOApplication 19295160
Show all 40 patent records
- Tricyclic Quinolone BCL6 Bifunctional DegradersAug 27, 2026 · Application 19659274Pending
- 1,8-NAPHTHYRIDIN-2-ONE Heterobifunctional BCL6 DegradersAug 20, 2026 · Application 18874504Pending
- Spirocyclic Dihydropyranopyrimidine Kras InhibitorsJan 22, 2026 · Application 19295160Pending
- Tetrahydroisoquinoline Heterobifunctional Bcl-xl DegradersSep 18, 2025 · Application 18858971Pending
- Tetrahydroisoquinoline Heterobifunctional Bcl-xl DegradersSep 11, 2025 · Application 18859011Pending
- Tricyclic Quinolone BCL6 Bifunctional DegradersSep 4, 2025 · Application 18872712Pending
- Quinolone BCL6 Bifunctional DegradersAug 28, 2025 · Application 18874511Pending
- Tricyclic Quinolone BCL6 Bifunctional DegradersAug 29, 2024 · Application 18329225Pending
- Tetrahydroisoquinoline Heterobifunctional Bcl-xl DegradersDec 7, 2023 · Application 18143454Pending
- Methods Of Treating Cancer Using An EZH2 Inhibitor And A Tricyclic Quinolone Heterobifunctional Degrader Of BCL6Application 63912179Pending
- Methods Of Treating Cancer Using An EZH2 Inhibitor And A Tricyclic Quinolone Heterobifunctional Degrader Of BCL6Application 63906248Pending
- Methods Of Treating Cancer Using An EZH2 Inhibitor And A Tricyclic Quinolone Heterobifunctional Degrader Of BCL6Application 63906227Pending
- Methods Of Treating Cancer Using An EZH2 Inhibitor And A Tricyclic Quinolone Heterobifunctional Degrader Of BCL6Application 63906261Pending
- Methods Of Treating Cancer Using An EZH2 Inhibitor And A Heterobifunctional Degrader Of BCL6Application 63906328Pending
- Tetrahydroisoquinoline Heterobifunctional Bcl-xl DegradersApplication PCTUS2025054404Pending
- Methods Of Treating Cancer Using An EZH2 Inhibitor And A Tricyclic Quinolone Heterobifunctional Degrader Of BCL6Application PCTUS2025059389Pending
- Methods Of Treating Cancer Using An EZH2 Inhibitor And A Tricyclic Quinolone Heterobifunctional Degrader Of BCL6Application 63906211Pending
- Tetrahydroisoquinoline Heterobifunctional Bcl-xl DegradersApplication 19146573Pending
- Macrocyclic Ras InhibitorsApplication PCTUS2025037162Pending
- Methods Of Treating Cancer Using An EZH2 Inhibitor And A Tricyclic Quinolone Heterobifunctional Degrader Of BCL6Application 63912263Pending
- Spirocyclic Dihydropyranopyrimidine Kras InhibitorsApplication 19144860Pending
- Macrocyclic Ras InhibitorsApplication 63830255Pending
- Macrocyclic Ras InhibitorsApplication 63830245Pending
- Methods Of Treating Cancer Using An EZH2 Inhibitor And A Heterobifunctional Degrader Of BCL6Application 63823629Pending
- Macrocyclic Ras InhibitorsApplication 63669884Pending
- Methods Of Treating Cancer Using An EZH2 Inhibitor And A Tricyclic Quinolone Heterobifunctional Degrader Of BCL6Application PCTUS2025059482Pending
- BCL6 Bifunctional Degraders And Methods And Intermediates For Synthesizing The SameApplication PCTUS2026017176Pending
- Methods For Treating Cancer Including A Heterobifunctional Degrader Of BCL6Application PCTUS2026017157Pending
- 2-CYCLOPROPYL-3,3,9-TRIFLUORO-1,2,3,4-TETRAHYDRO-[1,4]OXAZEPINO[2,3-C]QUINOLIN-6(7H)-ONE BCL6 ModulatorsApplication PCTUS2026017173Pending
- Methods For Treating Cancer Including A Heterobifunctional Degrader Of BCL6Application PCTUS2026017051Pending
- Macrocyclic Ras InhibitorsApplication PCTUS2025037172Pending
- Pyridopyrimidine Bifunctional Kras DegradersApplication 63888604Pending
- Methods Of Treating Cancer Using An EZH2 Inhibitor And A Tricyclic Quinolone Heterobifunctional Degrader Of BCL6Application 63912258Pending
- Combination Methods Of Treating Cancer Including A Heterobifunctional Degrader Of BCL6Application 63912207Pending
- Spirocyclic Kras InhibitorsApplication PCTUS2026015092Pending
- Spirocyclic Kras InhibitorsApplication 63888813Pending
- Combination Methods Of Treating Cancer Including A Heterobifunctional Degrader Of BCL6Application 63864000Pending
- Tetrahydroisoquinoline Heterobifunctional Bcl-xl DegradersApplication 19147014Pending
- BCL6 Bifunctional Degraders And Methods And Intermediates For Synthesizing The SameApplication 63829473Pending
- Degraders Of Tead Transcription FactorsApplication PCTUS2025043376Pending
Related companies, and why
- Ratio Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- NANOMEDTRIX LLCSimilar federal contract value in Biotech · null in contracts
- Boundless Bio, Inc.Similar federal contract value in Biotech · null in contracts
- ESTRIGENIX THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- Cognito Therapeutics Ltd.Similar federal contract value in Biotech · null in contracts
- Kyverna TherapeuticsSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .